This study aims to compare safety and efficacy in an exploratory manner between a Tegoprazan triple therapy and a RAPAE01 triple therapy in H. pylori positive patients.

A Randomized, Double-Blind, Active-controlled, Multicenter, Pilot Study to Investigate the Safety and Efficacy of a Tegoprazan triple therapy and a RAPAE01 triple therapy in H. pylori positive patients.

Inclusion Criteria:

• H. pylori positive at screening
• Subjects who have upper gastrointestinal disease

Exclusion Criteria:

• Having received prior therapy for eradication of H. pylori
• Prior use of P-CAB, proton pump inhibitors (PPIs), H2 receptor blockers within 14 days
• Prior use of H. pylori eradication effective antibiotics, bismuth within 28 days